Differential Network Analysis Applied to Preoperative Breast Cancer Chemotherapy Response

Autor(en): Warsow, Gregor
Struckmann, Stephan
Kerkhoff, Claus 
Reimer, Toralf
Engel, Nadja
Fuellen, Georg
Stichwörter: B-MYB; CELLS; CLASSIFICATION; EXPRESSION; IN-VIVO; LEUCINE-ZIPPER KINASE; MELK; Multidisciplinary Sciences; PROTEIN; REGULATOR; Science & Technology - Other Topics; SUBTYPES
Erscheinungsdatum: 2013
Herausgeber: PUBLIC LIBRARY SCIENCE
Journal: PLOS ONE
Volumen: 8
Ausgabe: 12
Zusammenfassung: 
In silico approaches are increasingly considered to improve breast cancer treatment. One of these treatments, neoadjuvant TFAC chemotherapy, is used in cases where application of preoperative systemic therapy is indicated. Estimating response to treatment allows or improves clinical decision-making and this, in turn, may be based on a good understanding of the underlying molecular mechanisms. Ever increasing amounts of high throughput data become available for integration into functional networks. In this study, we applied our software tool ExprEssence to identify specific mechanisms relevant for TFAC therapy response, from a gene/protein interaction network. We contrasted the resulting active subnetwork to the subnetworks of two other such methods, OptDis and KeyPathwayMiner. We could show that the ExprEssence subnetwork is more related to the mechanistic functional principles of TFAC therapy than the subnetworks of the other two methods despite the simplicity of ExprEssence. We were able to validate our method by recovering known mechanisms and as an application example of our method, we identified a mechanism that may further explain the synergism between paclitaxel and doxorubicin in TFAC treatment: Paclitaxel may attenuate MELK gene expression, resulting in lower levels of its target MYBL2, already associated with doxorubicin synergism in hepatocellular carcinoma cell lines. We tested our hypothesis in three breast cancer cell lines, confirming it in part. In particular, the predicted effect on MYBL2 could be validated, and a synergistic effect of paclitaxel and doxorubicin could be demonstrated in the breast cancer cell lines SKBR3 and MCF-7.
ISSN: 19326203
DOI: 10.1371/journal.pone.0081784

Show full item record

Google ScholarTM

Check

Altmetric